A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)

NCT00485836 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

392

Enrollment

INDUSTRY

Sponsor class

Conditions

Macular Edema
Retinal Vein Occlusion

Interventions

DRUG: Sham injection
DRUG: Ranibizumab injection 0.3 mg
DRUG: Ranibizumab injection 0.5 mg

Sponsor

Genentech, Inc.